Cannabis research no longer stops at national lines. As medical programs mature across the US, Canada, the UK, and beyond, international clinical trial collaboration has become the fastest route to credible data, regulatory approval, and commercial scale. Yet most...
Patients are asking about medical cannabis faster than most providers can answer. Many physicians never received formal training on cannabinoid science, dosing, drug interactions, or the patchwork of state regulations that shape what they can legally recommend. That...
Cannabinoid-based pharmaceuticals are moving from promise to practice, with a growing pipeline of FDA-reviewed candidates targeting epilepsy, pain, sleep, and beyond. Yet the path from molecule to market remains one of the most demanding in the industry. This session...
The 280E landscape is shifting faster than most operators can track, and the decisions you make now could mean recovering serious cash or leaving it on the table. This session translates recent 280E developments into clear, actionable tax strategy for cannabis...
The hemp industry is approaching a challenging regulatory path. Pending federal and state enforcement deadlines aim to close the loophole that let intoxicating, hemp-derived products flourish, redefining legal hemp by total-THC content rather than delta-9 alone. For...
